| Literature DB >> 21738731 |
Curi Kim1, Jamal A Ahmed, Rachel B Eidex, Raymond Nyoka, Lilian W Waiboci, Dean Erdman, Adan Tepo, Abdirahman S Mahamud, Wamburu Kabura, Margaret Nguhi, Philip Muthoka, Wagacha Burton, Robert F Breiman, M Kariuki Njenga, Mark A Katz.
Abstract
BACKGROUND: Many acute respiratory illness surveillance systems collect and test nasopharyngeal (NP) and/or oropharyngeal (OP) swab specimens, yet there are few studies assessing the relative measures of performance for NP versus OP specimens.Entities:
Mesh:
Year: 2011 PMID: 21738731 PMCID: PMC3128075 DOI: 10.1371/journal.pone.0021610
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Case definitions of influenza-like illness and severe acute respiratory infection adapted from World Health Organization1 , 2
|
|
|
|
| 1. Temperature ≥38° |
| 2. Cough or sore throat |
| 3. Does not meet criteria for SARI |
|
|
|
|
| • Respiratory rate of >60 per minute• Severe chest indrawing• Nasal flaring (when an infant breathes in)• Grunting (when an infant breathes out)• Temperature ≥38°C• Temperature <35.5°C• Pulse oxygenation <90% |
|
|
| 1. Cough or difficulty breathing |
| 2. AND any one of the following: |
| • Breathing >50/minute for infant aged 2 months to <1year• Breathing >40/minute for child aged 1 to <5 years• Chest indrawing or stridor in a calm child• Unable to drink or breast feed• Vomits everything• Convulsions• Lethargic or unconscious• Pulse oxygenation <90% |
|
|
| 1. Temperature ≥38.0°C |
| 2. Cough or sore throat |
| 3. Shortness of breath or difficulty breathing |
1. World Health Organization. Handbook: IMCI Integrated Management of Childhood Illness 2005. Available from: http://whqlibdoc.who.int/publications/2005/9241546441.pdf.
2. World Health Organization. WHO Regional Office for Europe guidance for influenza surveillance in humans. 2009. Available from: http://www.euro.who.int/__data/assets/pdf_file/0020/90443/E92738.pdf.
Primers and probes used in this study.
| Assay | Primer/Probe Sequence (5′ to 3′) |
| Adenovirus |
|
|
| |
|
| |
| hMPV |
|
|
| |
|
| |
| Influenza A |
|
|
| |
|
| |
| Influenza B |
|
|
| |
|
| |
| PIV type 1 |
|
|
| |
|
| |
| PIV type 2 |
|
|
| |
|
| |
| PIV type 3 |
|
|
| |
|
| |
| RSV |
|
|
| |
|
|
1. hMPV, human metapneumovirus; PIV, parainfluenza virus; RSV, respiratory syncytial virus.
2. F, forward primer.
3. R, reverse primer.
4. P, probe.
5. “T”, internal quencher.
Demographic characteristics of 2331 patients with influenza-like illness and severe acute respiratory illness from whom paired nasopharyngeal and oropharyngeal swabs were collected – Kenya, 2009–2010.
| Category | Subcategory | N (%) |
| Illness | Severe acute respiratory illness | 1577 (67.7%) |
| Influenza-like illness | 754 (32.3%) | |
| Age | Median | 1 year |
| Range | 1 month–70 years | |
| <5 years | 1902 (81.6%) | |
| 5–17 years | 344 (14.8%) | |
| >18 years and older | 85 (3.6%) | |
| Sex | Female | 1074 (46.1%) |
| Male | 1257 (53.9%) | |
| Location | North Eastern Province | 1233 (52.9%) |
| Rift Valley Province | 1098 (47.1%) |
Kappa and sensitivity values of paired nasopharyngeal (NP) swabs and oropharyngeal (OP) swabs for respiratory viruses in all patients (n = 2331) – Kenya, 2009-2010.
| Virus | No. positive NP and/or OP swabs | No. positive NP swabs | No. positive OP swabs | % missed with one swab | Kappa statistic | NP sensitivity (95% CI) | OP sensitivity (95% CI) |
|
| Adenovirus | 679 | 391 | 492 | 27.5% | 0.33 (0.28–0.38) | 57.6 (53.8–61.4) | 72.4 (68.8–75.7) | < 0.01 |
| hMPV | 201 | 158 | 139 | 0.62 (0.55–0.69) | 78.6 (72.3–84.1) | 69.2 (62.3–75.5) | 0.08 | |
| Influenza A | 256 | 181 | 220 | 14.1% | 0.70 (0.64–0.75) | 70.7 (64.7–76.2) | 85.9 (81.1–90) | < 0.01 |
| 2009 H1N1 | 125 | 88 | 114 | 8.8% | 0.75 (0.68–0.82) | 70.4 (61.6–78.2) | 91.2 (84.8–95.5) | < 0.01 |
| H1N1 | 6 | 6 | 5 | 0.9 (0.73–1.0) | 100 (54.1–100) | 83.3 (35.9–99.6) | 1.00 | |
| H3N2 | 54 | 45 | 50 | 0.86 (0.79–0.94) | 83.3 (70.7–92.1) | 92.6 (82.1–97.9) | 0.27 | |
| unsubtypable | 71 | 33 | 48 | -0.68 (-0.86–0.5) | 46.5 (34.5–58.7) | 67.6 (55.5–78.2) | 0.07 | |
| Influenza B | 65 | 55 | 40 | 15.4% | 0.62 (0.51–0.74) | 83.3 (72.1–91.4) | 61.5 (48.6 -73.3) | 0.02 |
| PIV 1 | 106 | 81 | 71 | 0.59 (0.50–0.69) | 76.4 (67.2–84.1) | 67.0 (57.2-75.8) | 0.24 | |
| PIV 2 | 56 | 48 | 22 | 14.3% | 0.39 (0.25–0.54) | 85.7 (73.8–93.6) | 39.3 (26.5–53.2) | < 0.01 |
| PIV 3 | 193 | 162 | 130 | 16.1% | 0.66 (0.59–0.72) | 83.9 (78.0–88.8) | 67.4 (60.3–73.9) | < 0.01 |
| RSV | 328 | 252 | 247 | 0.65 (0.59–0.70) | 76.8 (71.9–81.3) | 75.3 (70.3–79.9) | 0.75 |
2009 H1N1, 2009 influenza A pandemic H1N1 virus; H1N1, seasonal influenza A H1N1 virus; H3N2, influenza A H3N2; RSV, respiratory syncytial virus; PIV, parainfluenza virus; hMPV, human metapneumovirus.
The percentage of cases that would have been missed if only the more sensitive swab had been used for viruses which had significant differences in sensitivities between swabs.
Kappa statistics: < 0 = poor; 0 – 0.2 = slight; 0.21 – 0.4 = fair; 0.41 – 0.6 = moderate; 0.61 – 0.8 = substantial; and 0.81 – 1 = almost perfect agreement. CI, confidence interval.
Kappa and sensitivity values of paired nasopharyngeal (NP) swabs and oropharyngeal (OP) swabs for respiratory viruses by illness category – Kenya, 2009-2010.
| Virus | No. positive NP and/or OP swabs | No. positive NP swabs | No. positive OP swabs | % missed with one swab | Kappa statistic | NP sensitivity (95% CI) | OP sensitivity (95% CI) |
|
|
| ||||||||
| Adenovirus | 515 | 308 | 367 | 28.7% | 0.32 (0.27–0.38) | 59.8 (55.4–64.1) | 71.3 (67.1–75.1) | <0.01 |
| hMPV | 150 | 116 | 101 | 0.59 (0.51–0.67) | 77.3 (69.8–83.8) | 67.3 (59.2–74.8) | 0.12 | |
| Influenza A | 168 | 125 | 141 | 0.71 (0.65–0.78) | 74.0 (66.7–80.4) | 83.9 (77.5–89.1) | 0.07 | |
| 2009 H1N1 | 77 | 53 | 71 | 7.8% | 0.75 (0.66–0.83) | 68.8 (57.3–78.9) | 92.2 (83.8–97.1) | <0.01 |
| H3N2 | 41 | 35 | 37 | 0.86 (0.77–0.94) | 85.4 (70.8–94.4) | 90.2 (76.9–97.3) | 0.75 | |
| Influenza B | 40 | 35 | 23 | 12.5% | 0.61 (0.47–0.76) | 85.4 (70.8–94.4) | 57.5 (40.9–73.0) | 0.02 |
| PIV 1 | 76 | 57 | 46 | 0.51 (0.39–0.63) | 75.0 (63.7–84.2) | 60.5 (48.6–71.5) | 0.15 | |
| PIV 2 | 44 | 39 | 15 | 11.4% | 0.36 (0.20–0.53) | 88.6 (75.4–96.2) | 34.1 (20.5–49.9) | <0.01 |
| PIV 3 | 155 | 134 | 99 | 13.5% | 0.64 (0.57–0.72) | 86.5 (80.0–91.4) | 63.9 (55.8–71.4) | <0.01 |
| RSV | 263 | 198 | 198 | 0.62 (0.56–0.68) | 75.3 (69.6–80.4) | 75.3 (69.6–80.4) | 1.00 | |
|
| ||||||||
| Adenovirus | 164 | 83 | 125 | 23.8% | 0.33 (0.24–0.42) | 50.6 (42.7–58.5) | 76.2 (69.0–82.5) | <0.01 |
| hMPV | 51 | 42 | 38 | 0.71 (0.59–0.82) | 82.4 (69.1–91.6) | 74.5 (60.4–85.7) | 0.52 | |
| Influenza A | 83 | 54 | 74 | 10.8% | 0.68 (0.58–0.77) | 65.5 (54.3–75.5) | 89.5 (81.1––95.1) | <0.01 |
| 2009 H1N1 | 48 | 35 | 43 | 0.76 (0.65–0.86) | 72.9 (58.2–84.7) | 89.6 (77.3–96.5) | 0.10 | |
| H3N2 | 13 | 10 | 13 | 0.87 (0.72–1.00) | 76.9 (46.2–95.0) | 100 (75.3–100.0) | 0.25 | |
| Influenza B | 25 | 20 | 17 | 0.64 (0.46–0.82) | 80.0 (59.3–93.2) | 68.0 (46.5–85.1) | 0.58 | |
| PIV1 | 30 | 24 | 25 | 0.77 (0.63–0.90) | 80.0 (61.4–92.3) | 83.3 (65.3–94.4) | 1.00 | |
| PIV2 | 12 | 9 | 7 | 0.49 (0.19–0.80) | 75.0 (42.8–94.5) | 58.3 (27.7–84.8) | 0.73 | |
| PIV3 | 38 | 28 | 31 | 0.70 (0.56–0.84) | 73.7 (56.9–86.6) | 81.6 (65.7–92.3) | 0.63 | |
| RSV | 65 | 54 | 49 | 0.72 (0.62–0.82) | 83.1 (71.7–91.2) | 75.4 (63.1–85.2) | 0.44 | |
2009 H1N1, 2009 influenza A pandemic H1N1 virus; H1N1, seasonal influenza A H1N1 virus; H3N2, influenza A H3N2; RSV, respiratory syncytial virus; PIV, parainfluenza virus; hMPV, human metapneumovirus.
The percentage of cases that would have been missed if only the more sensitive swab had been used for viruses which had significant differences in sensitivities between swabs.
Kappa statistics: <0 = poor; 0–0.2 = slight; 0.21–0.4 = fair; 0.41–0.6 = moderate; 0.61–0.8 = substantial; and 0.81–1 = almost perfect agreement. CI, confidence interval.